SPOTLIGHT -
Optometry Giving Sight shares VEW plans, previews AAOpt activities
OGS has begun its funding season as the organization looks ahead to wrapping up 2023 and kicking off 2024.
FDA approves Ryzumvi (phentolamine ophthalmic solution 0.75%) for the treatment of pharmacologically-induced mydriasis
Ocuphire Pharma and Viatris developed the drug together for the reversal of pharmacologically-induced mydriasis (RM) produced by adrenergic agonist or parasympatholytic agents.
Prevent Blindness joins World Sight Day global initiative of “Love Your Eyes At Work”
The theme calls on employers, insurers, and policy makers to consider how they can contribute to improved access to vision and eye health care.
Handling comorbidities prior to surgery
Addressing issues prior to referral will facilitate the referral process and enable more efficient care for your patient as well as maximize outcomes.
How to implement a custom contact lens fitting model into your practice
Luis Rojas, OD, shares his tips and tricks for getting the best fit for multifocal contact lenses, as well as how to leverage custom fittings as a service as a marketing tool.
Vision By Design 2023 brought comprehensive myopia management and ortho-k education
The American Academy of Orthokeratology & Myopia Control-hosted conference was held September 5-9.
Early CAM therapy kick-starts healing
Combination therapy may reduce adverse events related to corticosteroids alone.
This week in optometry: September 18-September 22
Catch up on what happened in optometry during the week of September 18-September 22.
Exciting things in the pipeline for the American Academy of Orthokeratology and Myopia Control
AAOMC is focusing on new membership growth, diversity, and how they can continue to move the needle in myopia management.
First comprehensive optometric history book published in the US in over 50 years.
Penned by David Goss, OD, PhD, the book was published by Pacific University Press.
Allergic conjunctivitis is prevalent in youngsters
Set your young patients—and their caregivers—up for success in treatment.
Study: Children with vision impairment have reduced quality of life
Research from Orbis International analyzes the overall wellbeing of children with common childhood vision problems.
Iveric Bio releases 24-month topline results from Phase 3 study of avacincaptad pegol intravitreal solution (IZERVAY) for geographic atrophy
According to the company, GATHER-2 24-month results met the primary objective of reducing the rate of GA growth in patients treated with IZERVAY compared to sham.
EyeCon 2023 empowers clinical engagement in a relaxed setting
Oluwatosin U. Smith, MD, shares why she is excited for the conference and why it is relevant for today’s ophthalmologists and optometrists.
Prevent Blindness seeks to bring awareness to eye inflammation with Inflammatory Eye Disease (IED) Awareness Week
The week of September 18-24 will be dedicated to educating the public on IEDs such as uveitis, keratitis, conjunctivitis and more.
FDA approves avacincaptad pegol intravitreal solution for treatment of geographic atrophy
The complement C5 inhibitor significantly reduced GA progression.
This week in optometry: September 11-September 15
Catch up on what happened in optometry during the week of September 11-September 15.
Cerebral visual impairment
Documenting the visual effects and simplifying visual life.
Dry age-related macular degeneration: The second city of AMD
Prevention should be at the forefront of the discussion.
The FDA issues warning letters to 8 companies for manufacturing/marketing unapproved ophthalmic drug products
Walgreens Boots Allianc Inc. and CVS Health are among the companies the FDA sent letters to for violating federal law.
